

SECTION THREE

HTA PRODUCT LINE TABLE

Product	Timeline	Methodology	Review Process	Audience	Available on Website
Information Requests					
Information Requests Levels	Actual work time	Not applicable	Not applicable	Originator of request	Not available
A	Up to ½ day				
B	Up to 1 day				
C	Up to 3 days				
Rapid Assessments					
Level 1 - QwikNote	1 to 2 weeks	<u>Search:</u> 5 years, English only <u>Approach:</u> List of abstracts	Information Specialist in consultation with Researcher	Originator of request	Listed on website and available on request
Level 2 - TechNote Completed request form	Up to 3 months	<u>Search:</u> Best available evidence, minimum 5 years <u>Databases:</u> MEDLINE/EMBASE and any relevant databases and grey literature <u>Approach:</u> Summary of evidence base, includes guidelines and ongoing clinical trials, expert opinion	One researcher Internal review (Director)	General distribution list for Alberta	Entire document
Level 3 – CompNote Completed request form and usually project scope	3 to 6 months	<u>Search:</u> Best available evidence, minimum 5 years <u>Databases:</u> MEDLINE/EMBASE and any relevant databases and grey literature <u>Approach:</u> Limited analyses, contextualization, includes guidelines and ongoing clinical trials	One researcher Internal review (Director) External review (4-6 weeks)	General distribution list for Alberta and selected stakeholders	Entire document

HTA Report					
HTA Report Completed request form and project scope	6 to 12 months	<u>Search:</u> Not limited by publication date, unless appropriate <u>Databases:</u> Comprehensive search of appropriate databases and grey literature <u>Data Sources:</u> Survey, administrative data analyses, statistical analyses <u>Approach:</u> Systematic review including formal assessment of methodological quality, meta analysis (if applicable), and contextualization	Two researchers Two researchers independently appraise quality, one researcher for data extraction (checked by a second researcher) <u>Internal</u> review (Director) <u>External</u> review (6 weeks)	General distribution plus selected experts/stakeholders	Entire document
Methodology/Research					
Information Paper	Not applicable	<u>Approach:</u> Focus on methodology, policy or administration (human resource) issues/concerns.	Varies <u>Internal</u> review (Director) <u>External</u> review - optional	Varies	Entire document

REFERENCES

1. Corabian P. *Gabapentin for non-malignant chronic pain*. Edmonton, Alberta: Alberta Heritage Foundation for Medical Research, Health Technology Assessment; 2004 Jul. Report: TechNote 47.
2. Harstall C. *Use of cannabis or cannabinoids for non-malignant chronic pain*. Edmonton, Alberta: Alberta Heritage Foundation for Medical Research, Health Technology Assessment; 2004 Feb. Report: TechNote 42.
3. Moga C, Harstall C, Tang Z. *Celecoxib for the treatment of pain in rheumatoid arthritis and osteoarthritis*. Edmonton, Alberta: Alberta Heritage Foundation for Medical Research; 2005 May. Report: Information Paper 24.
4. Moga C, Harstall C. *COX-2 inhibitors (etoricoxib) for the treatment of non-malignant chronic low back pain*. Edmonton, Alberta: Alberta Heritage Foundation for Medical Research, Health Technology Assessment; 2005 Jan, updated 2005 Apr. Report: TechNote 48.
5. Ospina M, Harstall C. *Multidisciplinary pain programs for chronic pain: evidence from systematic reviews*. Edmonton, Alberta: Alberta Heritage Foundation for Medical Research, Health Technology Assessment; 2003 Jan. Report: HTA 30.
6. Scott A, Guo B. *Trigger point injections for chronic non-malignant musculoskeletal pain*. Edmonton, Alberta: Alberta Heritage Foundation for Medical Research, Health Technology Assessment; 2005 Jan. Report HTA 35.